Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal Benefit

The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in high-fibrosis patients without clear mortality advantage.
Superior Long-Term Hemodynamics with Self-Expanding Valves in Small Failed Bioprostheses: 3-Year Insights from the LYTEN Trial

Superior Long-Term Hemodynamics with Self-Expanding Valves in Small Failed Bioprostheses: 3-Year Insights from the LYTEN Trial

The 3-year analysis of the LYTEN trial reveals that self-expanding valves (SEV) significantly outperform balloon-expandable valves (BEV) in hemodynamic metrics for valve-in-valve TAVR in patients with small surgical bioprostheses, although clinical outcomes and quality of life improvements remain comparable.
Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications

Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications

A life cycle assessment found SAVR emits ~620–750 kg CO2e per case—roughly double OR- or cath-lab TAVR (~280–360 kg CO2e). ICU length of stay and postoperative care were the dominant contributors, highlighting targets for low-carbon perioperative pathways and policy-level decision-making.